LEQEMBI(R) Pen (Subcutaneous Formulation of LEQEMBI(R)) Approved in Japan for the Treatment of Early Alzheimer’s Disease

TOKYO and CAMBRIDGE, Mass., September 18, 2026 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that “LEQEMBI® Pen”, the subcutaneous (SC) formulation of the anti-amyloid beta (Aβ) protofibril antibody “LEQEMBI®” (brand name, generic name: lecanemab) has been approved in Japan as a new route of administration.LEQEMBI Pen is an autoinjector formulation that enables administration by a care partner or patient self-administration…
Read More